Systemic inflammation, intestine, and XXXX .

@entity1 @entity533 @entity1522 @entity2958 @entity19 @entity26 @entity95 @entity1675 @entity731 @entity165
Serum @entity533 ( @entity533 ) has been shown to act as an important guardian against cellular damage from oxidized lipids in low-density lipoprotein (LDL), plasma membrane, against toxic agents such as pesticide residues including @entity2958 and against bacterial endotoxin. @entity533 associated with circulating high-density lipoprotein (HDL) has the ability to prevent the generation of pro inflammatory oxidized phospholipids by reactive @entity26 species. The activities of the HDL-associated @entity533 and several other anti-inflammatory factors in HDL are in turn negatively regulated by these oxidized lipids. In @entity95 , @entity19 , and @entity1 there appears to be an increase in the formation of these oxidized lipids during the acute phase response. This results in the association of acute phase proteins with HDL and inhibition of the HDL-associated @entity533 that renders HDL pro inflammatory.In populations, low serum HDL- @entity165 is a risk factor for @entity731 and efforts are directed toward therapies to improve the quality and the relative concentrations of LDL and HDL. @entity1675 ( @entity1675 ) has been shown to reduce @entity731 in laboratory animals. @entity1675 , however, is a large protein that is costly and needs to be administered parenterally. Our group has developed @entity1675 mimetic peptides that are much smaller than @entity1675 (18 @entity1522 long vs 243 in @entity1675 itself). These HDL mimetic peptides are much more effective in removing the oxidized phospholipids and other oxidized lipids. They improve LDL and HDL composition and function and reduce lesion formation in animal models of @entity731 . Following is a brief description of some of the HDL mimetic peptides that can improve HDL and the effect of the peptide on @entity533 activity.
